Acute myeloid leukemia with complex cytogenetic abnormalities associated with long-term use of oral colloidal silver as nutritional supplement – Case report and review of literature
Restricted accessCase reportFirst published online January, 2020
Acute myeloid leukemia with complex cytogenetic abnormalities associated with long-term use of oral colloidal silver as nutritional supplement – Case report and review of literature
We report a case of acute myeloid leukemia with complex cytogenetic abnormalities suggestive of preexisting myelodysplastic syndrome in a patient with habitual ingestion of colloidal silver as nutritional supplement for over 10 years and the medical literature is reviewed.
LansdownAB. Physiological and toxicological changes in the skin resulting from the action and interaction of metal ions. Crit Rev Toxicol1995; 25: 397–462.
2.
HadrupNLamHR. Oral toxicity of silver ions, silver nanoparticles and colloidal silver – a review. Regul Toxicol Pharmacol2014; 68: 1–7.
3.
LansdownAB. Silver in health care: antimicrobial effects and safety in use. Curr Probl Dermatol2006; 33: 17–34.
4.
FoxCLJr. Silver sulfadiazine – a new topical therapy for Pseudomonas in burns. Therapy of Pseudomonas infection in burns. Arch Surg1968; 96: 184–188.
5.
vanHPGasheBAAhmadJ. Colloidal silver as an antimicrobial agent: fact or fiction?. J Wound Care2004; 13: 154–155.
6.
MorrillKMayKLeekD, et al.Spectrum of antimicrobial activity associated with ionic colloidal silver. J Altern Complement Med2013; 19: 224–231.
7.
TagliettiAAz FernandezYAAmatoE, et al.Antibacterial activity of glutathione-coated silver nanoparticles against Gram positive and Gram negative bacteria. Langmuir2012; 28: 8140–8148.
8.
RajivSDrillingABassiouniA, et al.Topical colloidal silver as an anti-biofilm agent in a Staphylococcus aureus chronic rhinosinusitis sheep model. Int Forum Allergy Rhinol2015; 5: 283–288.
9.
ScottJRKrishnanRRotenbergBW, et al.The effectiveness of topical colloidal silver in recalcitrant chronic rhinosinusitis: a randomized crossover control trial. J Otolaryngol Head Neck Surg2017; 46: 64.
10.
BaralVRDewarALConnettGJ. Colloidal silver for lung disease in cystic fibrosis. J R Soc Med2008; 101: S51–S52.
11.
GriffithRDSimmonsBJYazdani AbyanehMA, et al.Colloidal silver: dangerous and readily available. JAMA Dermatol2015; 151: 667–668.
12.
FungMCWeintraubMBowenDL. Colloidal silver proteins marketed as health supplements. JAMA1995; 274: 1196–1197.
13.
Department of Health and Human Services (HHS) PHSP, Food and Drug Administration (FDA). Over the counter drug products containing colloidal silver ingrediets or silver salts: final rule. Fed Regist1999; 64: 44653–44658.
14.
KaewamatawongTBanlunaraWManeewattanapinyoP, et al.Acute and subacute pulmonary toxicity caused by a single intratracheal instillation of colloidal silver nanoparticles in mice: pathobiological changes and metallothionein responses. J Environ Pathol Toxicol Oncol2014; 33: 59–68.
15.
LansdownAB. Critical observations on the neurotoxicity of silver. Crit Rev Toxicol2007; 37: 237–250.
16.
BeutlerBDLeeRACohenPR. Localized cutaneous argyria: report of two patients and literature review. Dermatol Online J2016, pp. 22: 13030/qt4wm1j7pt, .
17.
Fernandez-FloresANguyenTCassarinoDS. Mucocutaneous hyperpigmentation in a patient with a history of both minocycline and silver ingestion. Am J Dermatopathol2017; 39: 916–919.
18.
WadheraAFungM. Systemic argyria associated with ingestion of colloidal silver. Dermatol Online J2005; 11: 12.
19.
ParkSWShinHTLeeKT, et al.Medical concern for colloidal silver supplementation: argyria of the nail and face. Ann Dermatol2013; 25: 111–112.
20.
SalujaSSBowenARHullCM. Resident rounds: part III – case report: argyria – a case of blue-gray skin. J Drugs Dermatol2015; 14: 760–761.
21.
BurgertJM. Argyria resulting from chronic use of colloidal silver in a patient presenting for colonoscopy. A A Case Rep2014; 3: 73–75.
22.
SchraubenSJBhanusaliDGSheetsS, et al.A case of argyria: multiple forms of silver ingestion in a patient with comorbid schizoaffective disorder. Cutis2012; 89: 221–224.
23.
ChungISLeeMYShinDH, et al.Three systemic argyria cases after ingestion of colloidal silver solution. Int J Dermatol2010; 49: 1175–1177.
24.
KwonHBLeeJHLeeSH, et al.A case of argyria following colloidal silver ingestion. Ann Dermatol2009; 21: 308–310.
25.
KimYSuhHSChaHJ, et al.A case of generalized argyria after ingestion of colloidal silver solution. Am J Ind Med2009; 52: 246–250.
26.
BakerCDFedericoMJAccursoFJ. Case report: skin discoloration following administration of colloidal silver in cystic fibrosis. Curr Opin Pediatr2007; 19: 733–735.
27.
KaloucheHWatsonARoutleyD. Blue lunulae: argyria and hypercopprecaemia. Australas J Dermatol2007; 48: 182–184.
28.
ChangALKhosraviVEgbertB. A case of argyria after colloidal silver ingestion. J Cutan Pathol2006; 33: 809–811.
29.
BrandtDParkBHoangM, et al.Argyria secondary to ingestion of homemade silver solution. J Am Acad Dermatol2005; 53: S105–S107.
30.
McKennaJKHullCMZoneJJ. Argyria associated with colloidal silver supplementation. Int J Dermatol2003; 42: 549.
31.
WhiteJMPowellAMBradyK, et al.Severe generalized argyria secondary to ingestion of colloidal silver protein. Clin Exp Dermatol2003; 28: 254–256.
32.
GulbransonSHHudJAHansenRC. Argyria following the use of dietary supplements containing colloidal silver protein. Cutis2000; 66: 373–374.
33.
MirsattariSMHammondRRSharpeMD, et al.Myoclonic status epilepticus following repeated oral ingestion of colloidal silver. Neurology2004; 62: 1408–1410.
34.
StepienKMTaylorA. Colloidal silver ingestion with copper and caeruloplasmin deficiency. Ann Clin Biochem2012; 49: 300–301.
35.
MullerGL. Experimental bone marrow reactions: I. Anemia produced by Collargol. J Exp Med1926; 43: 533–553.
36.
ShouseSSWhippleGHI. Effects of the intravenous injection of colloidal silver upon the hematopoietic system in dogs. J Exp Med1931; 53: 413–420.
37.
JarrettFEllerbeSDemlingR. Acute leukopenia during topical burn therapy with silver sulfadiazine. Am J Surg1978; 135: 818–819.
38.
LansdownAB. A pharmacological and toxicological profile of silver as an antimicrobial agent in medical devices. Adv Pharmacol Sci2010; 2010: 910686, .
39.
ChooWHParkCHJungSE, et al.Long-term exposures to low doses of silver nanoparticles enhanced in vitro malignant cell transformation in non-tumorigenic BEAS-2B cells. Toxicol In Vitro2016; 37: 41–49.
40.
VilaLMarcosRHernandezA. Long-term effects of silver nanoparticles in caco-2 cells. Nanotoxicology2017; 11: 771–780.
